Klebsiella pneumoniae

ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections

Retrieved on: 
木曜日, 4月 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Stenotrophomonas maltophilia, Mortality, Genetically modified bacteria, Cefiderocol, Safety, Kidney disease, Infection, Survival, Immunosuppression, Diabetes, Pseudomonas aeruginosa, ECCMID, Head, Urinary tract infection, CHAI, Patient, Hospice and palliative medicine, Gram-negative bacteria, Klebsiella pneumoniae, Chronic obstructive pulmonary disease, Pharmaceutical industry

Please see below under About Cefiderocol for full indications of Fetroja in the U.S.

Key Points: 
  • Please see below under About Cefiderocol for full indications of Fetroja in the U.S.
  • Additionally,19.5% of patients had polymicrobial infections.1
    The study included 261 critically ill adult patients with limited treatment options who received cefiderocol for less than 28 days as part of Shionogi’s Early Access Program in Spain.
  • Real-world evidence is particularly important when reviewing antibiotic use for multidrug-resistant pathogens because of the challenges of conducting randomized clinical trials.
  • We also know how important it is to ensure equitable, global, access to essential medicines like cefiderocol.

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
木曜日, 4月 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

Retrieved on: 
火曜日, 2月 20, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Hospitals, Clinical Trials, Senior, Urinary tract infection, Infection, Multimedia, MDR, MD, Physician, Marketing, Antimalarial medication, Klebsiella pneumoniae, Pyelonephritis, NEJM, Safety, Therapy, Patient, UTI, AP, Melinta Therapeutics, Medication, Pseudomonas aeruginosa, Fungal infection, Pharmaceutical industry

Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), including those with bacteremia.

Key Points: 
  • Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), including those with bacteremia.
  • The results showed that cefepime-taniborbactam was superior to meropenem for the treatment of complicated UTI that included acute pyelonephritis, with a similar safety profile to meropenem.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240220917017/en/
    “Gram-negative infections such as cUTI have become increasingly difficult to treat due to acquired bacterial resistance to multiple classes of antibiotics.

LG'S HOME LIFESTYLE SOLUTIONS PRESENT COMFORT AND CONVENIENCE AT KBIS 2024

Retrieved on: 
金曜日, 2月 23, 2024
Filtration, Magnesium, Atmosphere, Dust, Las Vegas Convention Center, KCL, KTR, Mineral, Klebsiella pneumoniae, Staphylococcus aureus, Chlorine, Clothing, Bacteria, Glass, Humidity, Drinking water, KBIS, Electronics, LG Electronics, Hygiene, Cool, Water, Calcium, LG, Pressure

SEOUL, South Korea, Feb. 23, 2024 /PRNewswire/ -- LG Electronics (LG) is unveiling a range of home lifestyle solutions at the 2024 Kitchen & Bath Industry Show (KBIS) in Las Vegas, USA, from February 27-29. The company's latest innovations, including the bath solution, PuriCare™ HydroTower and system ironing, use sophisticated technologies and user-friendly design to elevate and enrich daily living.

Key Points: 
  • LG is expanding enhanced customer experience to the bathroom, one of the main living spaces in the home, by presenting a bath solution that provides convenience and comfort.
  • For greater comfort in the shower, LG's Smart Bath and Shower Purifier leverages thermostatics to maintain the selected water temperature.
  • Making its international debut at KBIS 2024, the HydroTower was successfully launched in South Korea last year, where it surpassed 10,000 units sold in only 50 days.
  • LG's new home solutions will be on display at the company's exhibition booth (West Hall #2343, Las Vegas Convention Center) during KBIS 2024 in Las Vegas, Nevada.

Basilea announces acquisition of preclinical antibiotics program from Spexis

Retrieved on: 
月曜日, 1月 15, 2024
Escherichia coli, World Health Organization, Patient, Gram-negative bacteria, Colistin, Partnership, Beta-lactam, Infection, Transmembrane protein, Bacteria, Klebsiella, Intellectual property, CHF, Lipopolysaccharide, Klebsiella pneumoniae, Vaccine

We are excited by the addition of this new program to our growing pipeline and to continue the development of this targeted antibiotics class, which has the potential to address an unmet medical need in the treatment of severe bacterial infections in the hospital.”

Key Points: 
  • We are excited by the addition of this new program to our growing pipeline and to continue the development of this targeted antibiotics class, which has the potential to address an unmet medical need in the treatment of severe bacterial infections in the hospital.”
    The antibiotics were developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program and selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria.
  • This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria.
  • The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator).2 This underscores the potential of this novel class of antibiotics.
  • In addition, Basilea assumes the rights and obligations of Spexis, including potential low single-digit percentage royalties on sales, under licensing agreements.

EFE Introduces a Fresh Take on Reading Glasses with Quantum Technology- A Stylish Leap Forward for Vision and Comfort

Retrieved on: 
火曜日, 1月 2, 2024
Heat, Klebsiella pneumoniae, Collection, Glasses, Salmonella, Somatosensory system, Staphylococcus aureus, EFE, Candida albicans, System, Bacteria, Escherichia coli, Comfort, Microscope

Blending the classic functionality of traditional reading glasses with the groundbreaking advancements of quantum technology, we are delivering an exceptional visual experience to our users.

Key Points: 
  • Blending the classic functionality of traditional reading glasses with the groundbreaking advancements of quantum technology, we are delivering an exceptional visual experience to our users.
  • We have expertly combined the usefulness of conventional reading glasses with the innovative capabilities of quantum technology.
  • This fusion offers an enhanced visual experience, taking a important leap forward for vision and comfort.
  • A Touch of Beauty in Every Look- In addition to being savvy, EFE reading glasses also care about appearance!

EFE Introduces Quantum Glasses: Pioneering the Future of Eyewear

Retrieved on: 
土曜日, 12月 16, 2023
Radiation protection, Klebsiella pneumoniae, Lens, Salmonella, Health, Staphylococcus aureus, Dry, Prescription, EFE, Klebsiella, Temperature, Escherichia, Escherichia coli, Candida albicans, Growth, System, Bacteria, Telescopic sight

New York, Dec. 15, 2023 (GLOBE NEWSWIRE) -- In a landmark innovation, EFE, the renowned eyewear brand from the Netherlands, proudly announces the launch of Quantum Glasses .

Key Points: 
  • New York, Dec. 15, 2023 (GLOBE NEWSWIRE) -- In a landmark innovation, EFE, the renowned eyewear brand from the Netherlands, proudly announces the launch of Quantum Glasses .
  • Crafted to meet the growing challenges of the digital era, Quantum Glasses represent a monumental leap in eyewear technology, offering unprecedented protection and enhancement for eyes frequently exposed to digital screens.
  • Quantum Glasses are a revolutionary product designed to combat the adverse effects of prolonged exposure to digital screens.
  • Unlike traditional blue light-blocking glasses, these glasses incorporate advanced features that go beyond simply alleviating digital eye strain.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
月曜日, 11月 27, 2023
Recce, Ross River virus, Simplex, ASX, Government, RCE, Klebsiella pneumoniae, PCT, Virus, Burn, Administration, Streptococcus pneumoniae, Patent, Disease, Staphylococcus aureus, Infection, Gonorrhea, Canada Revenue Agency, Inhalation, Shingles, Pseudomonas aeruginosa, Biology, COVID-19, Streptococcus pyogenes, Viral, EBV, Escherichia coli, HIV, Coronavirus, SARS-CoV-2, Cytomegalovirus, Staphylococcus, Urinary tract infection, Bacteria, Neisseria meningitidis, HCMV, Science, Skin, Pharmaceutical industry

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

Retrieved on: 
火曜日, 12月 26, 2023
Hyperphosphatemia, Quality of life, Immunotherapy, Immune system, Klebsiella pneumoniae, FDA, PD-1, Renal cell carcinoma, Research, Bladder cancer, TKI, Cancer, Clinical trial, Pseudomonas aeruginosa, Acinetobacter baumannii, Chronic kidney disease, Phosphorus, Kidney disease, NMPA, BCG, Proteinuria, Escherichia coli, Kidney, Edema, National Medical Products Administration, Patient, Drug resistance, CKD, Dialysis, Gram-negative bacteria, Pharmaceutical industry

On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria.

Key Points: 
  • On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria.
  • Drug resistance of antibiotics, especially carbapenem resistance, in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa has risen year by year.
  • On December 12, NMPA has approved a clinical trial for JMKX003142 to treat renal edema.
  • On December 12, FDA has approved a clinical trial for JMKX000197 to treat BCG-unresponsive non-muscle-invasive bladder cancer, and earlier on October 19, NMPA has approved the clinical trial.

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Retrieved on: 
火曜日, 11月 14, 2023
Webcast, Research, POC, European Medicines Agency, Lysin, Therapy, Infection, Conference call, Bank statement, S. aureus, Escherichia coli, S, Risk, Mortality, Phage therapy, EMA, ANSM, Patient, CET, AAC, FDA, Klebsiella pneumoniae, Fungal infection, Health, Pseudomonas aeruginosa, Partnership, CMC, IVD, EI, Cryptocurrency, Pharmaceutical industry, Dietary supplement, Medical device, Vaccine, Conference, Bloodstream infections

The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.

Key Points: 
  • The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.
  • Key financial figures for the first nine months of 2023 compared with the same period of the previous year are summarized below.
  • In the context of the Erytech-Pherecydes merger, PHAXIAM’s consolidated financial statements in IFRS standards include ex-Pherecydes financial results as from the date of the merger, i.e.
  • Consequently, PHAXIAM’s P&L information for the first 9 months of 2023 include 9 months of ex-Erytech activities and ex-Pherecydes activities since June 23, 2023.